Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook
Source: SeekingAlpha
2026-02-25 12:58:32 ET
More on Ionis Pharmaceuticals
- Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
- Ionis Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
- Ionis Pharmaceuticals Q4 2025 Earnings Preview
- Ionis, Otsuka win EU nod for hereditary angioedema therapy
Read the full article on Seeking Alpha
For further details see:
Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook
Ionis Pharmaceuticals Inc.
NASDAQ: IONS
IONS Trading
1.78% G/L:
$75.27 Last:
1,637,964 Volume:
$73.50 Open:
IONS Latest News
February 27, 2026 07:00:00 am
Ionis to present new data supporting DAWNZERA(TM) (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
February 26, 2026 07:00:00 am
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
IONS Stock Data
$13,602,609,524
157,763,059
0.53%
186
N/A
Biotechnology & Life Sciences
Healthcare
US
Carlsbad
